ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3

Xiong, Xifeng; Lai, Xudong; Zhang, Jinli; Meng, Qingqi; Wang, Pengzhen; Qin, Shengnan; Liu, Wei; Wang, Yongxuan; Yao, Zhuo; Wang, Di; Li, Xiaojian*; Liu, Zhihe*; Miao, Haixiong*广东药学院; 广州医学院
Bioscience Reports2022-9-22DOI: 10.1042/BSR20221002
2被引5阅读
引用收藏
分享

摘要

Worldwide, ovarian cancer (OC) is the seventh common cancer and the second most common cause of cancer death in women. Due to high rates of relapse, there is an urgent need for the identification of new targets for OC treatment. The far-upstream element binding protein 1 (FBP1) and enhancer of zeste homolog 2 (EZH2) are emerging proto-oncogenes that regulate cell proliferation and metastasis. In the present study, Oncomine data analysis demonstrated that FBP1 was closely associated with the development of OC, and The Cancer Genome Atlas (TCGA) data analysis indicated that there was a positive correlation between FBP1 and EZH2 in ovarian tissues. Moreover, we found that FBP1 knockdown suppressed tumor formation in nude mice and cisplatin resistance of OC cells, but the role of FBP1 in the cisplatin resistance of OC cells remained unclear. In addition, we verified physical binding between FBP1 and EZH2 in OC cells, and we demonstrated that FBP1 knockdown enhanced cisplatin cytotoxicity in OC cells and down-regulated EZH2 expression and trimethylation of H3K27. These results suggested that FBP1 increases cisplatin resistance of OC cells by up-regulating EZH2/H3K27me3. Thus, FBP1 is a prospective novel target for the development of OC treatment.

学科与关键词

关键词
ELEMENT-BINDING PROTEIN-1HISTONE METHYLTRANSFERASE EZH2HEPATOCELLULAR-CARCINOMADRUG-RESISTANCETARGETING EZH2CELL CARCINOMAC-MYCEXPRESSIONOVEREXPRESSIONBREAST
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Bioscience Reports
发表日期
2022-09-22
卷期
第 42 卷, 第 9 期
页码
BSR20221002
DOI
10.1042/BSR20221002
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81902802]; Guangzhou Science and Technology Project [202102010058, 202102010060, 202102080231, 202201010020]; Medical Science and Technology Research Foundation of Guangdong [A2018063]; Traditional Chinese Medicine Bureau of Guangdong Province [20191260, 20211229, 20211298]; Guangzhou Municipal Health Commission [20201A011020, 20211A011020, 20221A011021]

作者

  • X

    Xiong, Xifeng (第一作者)

  • L

    Lai, Xudong

查看全部 13 位作者收起作者
  • Z

    Zhang, Jinli

  • M

    Meng, Qingqi

  • W

    Wang, Pengzhen

  • Q

    Qin, Shengnan

  • L

    Liu, Wei

  • W

    Wang, Yongxuan

  • Y

    Yao, Zhuo

    guangdong pharmaceut univ

  • W

    Wang, Di

    2 · guangzhou med univ

  • L

    Li, Xiaojian (通讯)

  • L

    Liu, Zhihe (通讯)

  • M

    Miao, Haixiong (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417